Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.
| Website | http://www.eligo-bioscience.com |
| Revenue | $8.5 million |
| Employees | 43 (27 on RocketReach) |
| Founded | 2014 |
| Address | 29 Rue Du Faubourg Saint-jacques, Paris, Ile de France 75014, FR |
| Industry | Biotechnology Research, Business Services General, Business Services |
| Keywords | Microbiome Therapeutics, Microbial Therapies, Genome Editing, Microbiome Research, Gut Microbiome, Drug Discovery, Microbial Engineering, Biotechnology, Pharmaceutical Research, Genetic Engineering, Synthetic Biology, Biopharmaceutical, Crispr Technology, Phage Therapy, Probiotics, Immuno-Oncology, Prebiotics |
| Competitors | Intellia Therapeutics, Inc., CRISPR Therapeutics, Editas Medicine, Caribou Biosciences, Beam Therapeutics, Avidity NanoMedicines, Scribetx, Regeneron, Novo Nordisk, Amgen +41 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541713 Companies |
Looking for a particular Eligo Bioscience employee's phone or email?
The Eligo Bioscience annual revenue was $8.5 million in 2026.
Aurélie Grienenberger is the COO of Eligo Bioscience.
27 people are employed at Eligo Bioscience.
Eligo Bioscience is based in Paris, Ile de France.
The NAICS codes for Eligo Bioscience are [5417, 541, 54, 54171, 541713].
The SIC codes for Eligo Bioscience are [87, 873].